Insulin Pump Standards: Confusion Persists Over Pre-Market Requirements
This article was originally published in The Gray Sheet
Executive Summary
Some companies in the insulin pump arena say FDA is asking for clinical data where it has not done so in the past and that new standards appear to have been established for the devices.
You may also be interested in...
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q4 2010
In the fourth quarter, medical device companies raised $1.1 billion, a third of which was represented by follow-on public offerings. Acquisitions were strong overall, holding steady with 15 transactions - the same as Q3 - but only slightly less in money paid, $6 billion. In vitro diagnostic/research companies, like medical device, also ended 2010 on a high note, with funding totaling $511 million in Q4. The majority of the money spent on IVD/research acquisitions came from Thermo Fisher Scientific's buy of Dionex for $2.1 billion.
Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q4 2010
In the fourth quarter, medical device companies raised $1.1 billion, a third of which was represented by follow-on public offerings. Acquisitions were strong overall, holding steady with 15 transactions - the same as Q3 - but only slightly less in money paid, $6 billion. In vitro diagnostic/research companies, like medical device, also ended 2010 on a high note, with funding totaling $511 million in Q4. The majority of the money spent on IVD/research acquisitions came from Thermo Fisher Scientific's buy of Dionex for $2.1 billion.
510(k) Reform Debate: Class IIb Or Not To Be?
As FDA prepares to announce planned 510(k) program reforms in the coming weeks, a key question is what will become of the proposal to split up Class II devices into two distinct categories.